Concomitant Rivaroxaban and Celecoxib Use
Rivaroxaban (Xarelto) and celecoxib (Celebrex) can be prescribed together only with careful bleeding-risk assessment because concomitant use of oral anticoagulants and NSAIDs increases bleeding risk. [1], [2], [3]
Interaction Risk
Celecoxib is an NSAID/COX-2 inhibitor and is associated with gastrointestinal mucosal injury and bleeding risk. [3] Rivaroxaban labeling includes NSAIDs among concomitant therapies that can increase bleeding risk. [1] A systematic review/meta-analysis reported increased bleeding risk with concomitant oral anticoagulants (including rivaroxaban) and NSAIDs (odds ratio 1.61; 95% CI 1.21 to 2.14). [2]
Practical Prescribing Approach
When celecoxib is used with rivaroxaban, bleeding monitoring and patient counseling for bleeding signs are recommended. [1], [2] Concomitant use should be avoided in patients with high baseline bleeding risk when feasible. [1], [2]
Important Patient Factors Increasing Harm
High-risk features for major bleeding with rivaroxaban include prior recent bleeding, active gastroduodenal ulcer, and other conditions listed in rivaroxaban risk guidance, which should prompt avoidance of NSAID co-therapy when possible. [1] Chronic NSAID exposure increases bleeding risk compared with no NSAID exposure. [2]
Alternative Analgesia Strategy
Acetaminophen is typically used as a lower-bleeding-risk alternative analgesic during anticoagulation in many clinical settings, while avoiding NSAIDs when possible. [4]
When Urgent Reassessment Is Required
Any signs or symptoms of blood loss during combined therapy should prompt prompt evaluation for bleeding. [1]
Clinical Bottom Line
Concomitant prescribing of Xarelto and Celebrex is associated with increased bleeding risk and should generally be limited to cases where the benefit clearly outweighs the risk, with close monitoring and avoidance of additional bleeding-risk medications. [1], [2]